ZOKINVY (lonafarnib) capsules: full prescribing information (2020)

Government Record · Eiger BioPharmaceuticals, Inc. / U.S. Food and Drug Administration · November 20, 2020

Eiger BioPharmaceuticals et al., 2020-11-20: The FDA-approved label for the only drug approved for Hutchinson-Gilford progeria syndrome: lonafarnib, a farnesyltransferase inhibitor, indicated to reduce mortality, dosed 115 mg/m2 twice daily rising to 150 mg/m2.

ZOKINVY is a farnesyltransferase inhibitor indicated in patients 12 months of age and older with a body surface area of 0.39 m2 and above (1): To reduce risk of mortality in Hutchinson-Gilford Progeria Syndrome

p. 1

Eiger BioPharmaceuticals et al., 2020-11-20: The FDA-approved label for the only drug approved for Hutchinson-Gilford progeria syndrome: lonafarnib, a farnesyltransferase inhibitor, indicated to reduce mortality, dosed 115 mg/m2 twice daily rising to 150 mg/m2. Record field transcription from the label's Indications and Usage highlights (labelled a record field, confidence MEDIUM per the record-field rule; the PDF page was opened and the text read directly). This is what the clinical record for progeria actually contains: lonafarnib only. Methylene blue is not an approved or trial-stage therapy for HGPS and does not appear in this label. Dose per label: start 115 mg/m2 twice daily, increase to 150 mg/m2 after 4 months, oral with food. Approval date 2020-11-20, NDA 213969. Related FDA approval package (same host): https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000Approv.pdf Study type: regulatory record.